<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151473">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02062489</url>
  </required_header>
  <id_info>
    <org_study_id>BCCT2014001</org_study_id>
    <nct_id>NCT02062489</nct_id>
  </id_info>
  <brief_title>Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is a multicentre, randomized,double-blind, prospective clinical trial
      which is sponsored by the researchers. The trial is designed to evaluate the effectiveness
      of tamoxifen as adjuvant therapy for ER(ER-α)/PR negative, ER-β positive operable breast
      cancer patients. 620 female ER(ER-α)/PR negative, ER-β(wild type ER-β1) positive operable
      breast cancer patients who had undergone neoadjuvant chemotherapy or directly modified
      radical mastectomy or breast-conserving surgery were randomly (1:1) enrolled to receive
      tamoxifen (20 mg per day) or placebo (2# per day) within 6 weeks after postoperative
      chemotherapy and/or radiation therapy if needed (according to 2013 NCCN breast cancer
      guideline). If the breast tumor's HER2 is positive, the patient can receive targeted therapy
      (Herceptin) combined with tamoxifen or placebo. The follow-up time will be ten years. The
      aim of this trial is to evaluate the effectiveness of tamoxifen as adjuvant therapy for
      ER(ER-α)/PR negative, ER-β positive operable breast cancer patients by comparing the DFS and
      OS between tamoxifen group and placebo group and to determine whether the percentage of
      positive ER-β expression is associated with the response to the hormone therapy in breast
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Disease-free survival of patients</measure>
    <time_frame>within 10 years after diagnosis</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival of patients</measure>
    <time_frame>within 10 years after diagnosis</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of adverse reactions</measure>
    <time_frame>within 5 years when patients is undergoing tamoxifen or placebo treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-free survival</measure>
    <time_frame>within 10 years after diagnosis</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">620</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Tamoxifen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20mg(2#)/day, PO, daily, five years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2#/day, PO, daily, five years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>20 mg(2#)/day, PO, daily</description>
    <arm_group_label>Tamoxifen</arm_group_label>
    <other_name>Nolvadex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2#/day, PO, daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patients signed the written informed consent

          -  The patients present with operable unilateral invasive breast cancers without distant
             metastasis(stage I, II, and III)

          -  The breast tumor's positive ER/PR rate is &lt;1%, and positive ER-beta1 rate is ≥10% by
             IHC.

          -  The patients have no history of neoadjuvant hormone therapy.

          -  The patients have normal cardiac functions by echocardiography.

          -  The patients' ECOG scores are ≤0-2.

          -  Female patient who is ≥ 18yrs, and ≤ 65yrs.

          -  The patients are non-pregnant, and disposed to practice contraception during the
             whole trial.

          -  The patients underwent neoadjuvant chemotherapy plus surgery or directly modified
             radical mastectomy or breast-conserving surgery (plus sentinel lymph node biopsy or
             axillary lymph node dissection) after diagnosis of breast cancer.

          -  The patients underwent chemotherapy, radiation therapy or targeted therapy(herceptin)
             after surgery according to the 2013 NCCN guideline.

          -  The results of patients' blood tests are as follows:

        Hb≥90g/L; WBC≥4.0×109/L; Plt≥100×109/L; Neutrophils≥1.5×109/L; ALT and AST ≤ triple of
        normal upper limit; TBIL ≤ 1.5 times of normal upper limit; Creatinine ≤ 1.25 times of
        normal upper limit.

        Exclusion Criteria:

          -  The patients have other cancers at the same time or have the history of other cancers
             except controlled skin basal cell carcinoma or skin squamous cell carcinoma or
             carcinoma in situ of cervix uterus;

          -  The patients have active infections that were not suitable for chemotherapy;

          -  The patients have severe non-cancerous diseases.

          -  The patients have history of neoadjuvant hormone therapy.

          -  The patients have bilateral breast cancers or DCIS or metastatic breast cancers.

          -  The patients are undergoing current administration of anti-cancer therapies, or are
             attending other clinical trials.

          -  The patients are pregnant or lactational, or they refuse to practice contraception
             during the whole trial.

          -  The patients are in some special conditions that they can't understand the written
             informed consent, such as they are demented or hawkish.

          -  The patients have allergic history or contraindication of tamoxifen.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erwei Song, M.D.,Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-Sen Memerial Hospital of Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qiang Liu, MD.PhD.</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erwei Song, M.D., Ph. D.</last_name>
    <phone>86-20-81332576</phone>
    <email>songerwei02@yahoo.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qiang Liu, M.D., Ph. D.</last_name>
    <phone>86-20-81332576</phone>
    <email>victorlq@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erwei Song, M.D.,Ph.D.</last_name>
      <email>songerwei02@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Qiang Liu</last_name>
      <email>victorlq@hotmail.com.com</email>
    </contact_backup>
    <investigator>
      <last_name>Erwei Song, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaoming Xie, M.D.,Ph.D.</last_name>
      <phone>86-13826109540</phone>
      <email>xiexm@sysucc.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Women and Children Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anqin Zhang</last_name>
      <phone>86-13925115929</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou Women and Children Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongmin Ma</last_name>
      <phone>86-13922723808</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou Army General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chenfang Zhang</last_name>
      <phone>86-13889908978</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wenbo Zheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhuanghong Wu, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xuli Meng, M.D.</last_name>
      <email>mxlmail@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 3, 2014</lastchanged_date>
  <firstreceived_date>February 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Erwei Song, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Vice President of Sun Yat-Sen Memorial Hospital</investigator_title>
  </responsible_party>
  <keyword>breast cancer,</keyword>
  <keyword>tamoxifen,</keyword>
  <keyword>ER/PR negative, ER-beta positive</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
